FDA Moves 12 Peptides Out of Category 2 for Independent Review

The FDA is removing twelve peptides — including BPC-157, KPV, LL-37, Thymosin Alpha-1, and SS-31 — from its Category 2 restricted list and sending them to the Pharmacy Compounding Advisory Committee for independent scientific review. If approved, these peptides will return to regulated 503A and 503B compounding pharmacies, restoring access to pharmacy-grade purity, proper storage, and physician-supervised use. This is not final approval. The review process is ongoing.

For nearly two years, some of the most clinically promising peptides in longevity and autoimmune medicine were restricted by the FDA from compounding pharmacies. This pushed them into an unregulated gray market where patients had no way to verify the purity, potency, or sterility of the products.

That just changed.

Twelve peptides are being removed from the FDA’s Category 2 and sent to the Pharmacy Compounding Advisory Committee (PCAC) for independent scientific review.

The 12 Peptides Under Review

• BPC-157 — tissue repair and gut support.

• KPV — anti-inflammatory signaling.

• LL-37 — innate immune modulation.

• Epitalon — aging-related research.

• MOTS-c — metabolic and cellular energy support.

• GHK-Cu — skin, tissue repair, and gene-expression research.

• Thymosin Alpha-1 — immune support.

• Thymosin Beta-4 (TB-500) — tissue repair and wound-healing research.

• Dihexa — experimental neurocognitive research.

• Selank — stress and anxiety research.

• Semax — attention and cognition research.

• SS-31 (Elamipretide) — mitochondrial support research.

Here’s Why I Care About This

These are peptides with decades of research behind them that address the mechanisms of what we treat every day: chronic inflammation, immune dysregulation, and accelerated cellular aging.

For autoimmune patients: Various peptides work upstream of the inflammatory cascade. They support the mucosal barrier and modulate intestinal immune signaling. They can help regulate the innate immune system without suppressing it, unlike conventional immunosuppressants.

For longevity patients: Various peptides have been studied for their effects on telomere length, AMPK — the same metabolic pathway triggered by exercise and caloric restriction, and improved insulin sensitivity and cellular energy production at the mitochondrial level.

What Regulated Access Means

Regulated compounding pharmacy access means pharmacy-grade purity, proper cold-chain storage, accurate dosing, and a prescribing provider who can monitor your response.

What Happens Next

This is not final approval, and the outcome is not guaranteed. But the direction is right.

Moving peptides out of a blanket ban and into evidence-based review is how regulatory science should function. Regulated access should follow.

What Peptides are Not

Peptides are not a replacement for a poor diet and lifestyle habits, nor for the foundational work of identifying your individual triggers. And they are not risk-free. Every peptide protocol should start with lab work and a provider who knows what they are looking at.

Peptide FAQs from our followers

Can BPC-157 promote cancer or tumor growth?

Published animal studies have not shown tumor promotion, but no long-term human oncological data exist. It’s a good idea to be screened before using them.

Do you have to take peptides for life?

Most peptides are used in defined on-off cycles, which prevents receptor downregulation and maintains the balance between tissue building and autophagy. Once the therapeutic goal is achieved, the peptide is discontinued and the patient is monitored.

Oral vs. injectable: which peptide form is better?

For BPC-157, opening the capsule in water and taking it on an empty stomach may help heal the gut lining. For systemic or musculoskeletal healing, subcutaneous injection has the highest bioavailability. Most peptides require injection because digestive enzymes break them down in the gut.

I have an autoimmune condition. Are peptides safe?

A variety of peptides are immunomodulatory, meaning they restore balance rather than broadly suppressing or stimulating the immune system. But some are immune-stimulating and may not be appropriate for every autoimmune presentation.

Which peptides help MCAS (mast cell activation syndrome)?

Mold and Lyme patients may become more symptomatic when using BPC-157 alone. The BPC-157/KPV/PEA combination is preferred for MCAS patients. If you have MCAS, peptide therapy should be introduced cautiously.

Can peptides help GI autoimmune conditions?

BPC-157 has the most published evidence for GI applications, including accelerated mucosal healing and protection against NSAID-induced gut injury. KPV reduces TNF-alpha levels, but these are tools within a broader strategy, not a standalone solution.

Do peptides have human clinical trials?

A few do, but many commonly discussed peptides lack strong human trial data. Where human studies exist, the quality and scope of evidence vary widely. If you choose to use peptides, do so knowing the evidence is predominantly preclinical.

How do I find a provider, and where should peptides come from?

Look for a provider trained in functional or integrative medicine with specific experience with peptides. They should source from a licensed 503A or 503B compounding pharmacy, require lab work before prescribing, individualize protocols, and require informed consent.

For guidance on peptide therapy, please reach out to us at PalmaVita Clinic.

Frequently Asked Questions About the FDA Peptide Review

What does it mean that peptides are being moved out of FDA Category 2?

Category 2 was a restricted list of substances the FDA considered too risky for compounding pharmacies to use. Peptides on that list could not legally be compounded for patients in the United States. Removing them from Category 2 sends them to the Pharmacy Compounding Advisory Committee (PCAC) for independent scientific review of the safety and efficacy data. If the committee approves, those peptides return to regulated compounding pharmacy access.

When will compounded peptides like BPC-157 be available again?

There is no firm date. The Pharmacy Compounding Advisory Committee will review each peptide individually, and access is contingent on a favorable review and final FDA action. The current step — removal from Category 2 and referral to PCAC — is a procedural advance, not a return to market. Patients should not assume access is imminent.

Why were these peptides restricted in the first place?

In 2023 and 2024, the FDA placed these peptides into Category 2 citing insufficient safety data, complex chemistry, or concerns about identity and potency. The blanket restriction did not distinguish between peptides with substantial research support and peptides with little. The current review process is designed to evaluate each peptide on its own evidence.

Is buying peptides online from research chemical sites legal or safe?

No. Peptides sold as “research chemicals” or “not for human use” are not regulated for purity, sterility, dosing accuracy, or storage. There is no oversight of what is actually in the vial. Patients have ended up with contaminated, underdosed, or misidentified products. The point of regulated compounding pharmacy access is to eliminate that gray market — not perpetuate it.

What is the difference between a 503A and 503B compounding pharmacy?

A 503A pharmacy compounds individualized prescriptions for specific patients based on a prescription from a licensed provider. A 503B pharmacy is an outsourcing facility that produces compounded medications in larger batches under FDA oversight, typically for clinics and hospitals. Both are regulated, both must meet purity and sterility standards, and both are legitimate sources for compounded peptides if the peptide is permitted.

Do I need a prescription to use peptides legally?

Yes. Peptides used therapeutically require a prescription from a licensed provider and should be dispensed by a regulated compounding pharmacy. A provider-supervised protocol includes baseline lab work, dosing tailored to your case, monitoring for response and side effects, and a defined cycle rather than open-ended use.